Comparison between Corona Remedies IPO and Jinkushal Industries IPO.
Corona Remedies IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Jinkushal Industries IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Corona Remedies IPO is up to ₹655.37 Cr whereas the issue size of the Jinkushal Industries IPO is up to ₹116.15 Cr. The final issue price of Corona Remedies IPO is ₹1,062.00 per share and of Jinkushal Industries IPO is ₹121.00 per share.
| Corona Remedies IPO | Jinkushal Industries IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹1,008.00 per share | ₹115.00 per share |
| Issue Price (Upper) | ₹1,062.00 per share | ₹121.00 per share |
| Issue Price (Final) | ₹1,062.00 per share | ₹121.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹54.00 per share | |
| Market Lot Size | 14 shares | 120 shares |
| Fresh Issue Size | 0 shares | 86,40,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹104.54 Cr |
| OFS Issue Size | 61,74,051 shares | 9,59,548 shares |
| OFS Issue Size (Amount) | up to ₹655.37 Cr | up to ₹11.61 Cr |
| Issue Size Total | 61,74,051 shares | 95,99,548 shares |
| Issue Size Total (Amount) | up to ₹655.37 Cr | up to ₹116.15 Cr |
Corona Remedies IPO opens on Dec 08, 2025, while Jinkushal Industries IPO opens on Sep 25, 2025. The closing date of Corona Remedies IPO and Jinkushal Industries IPO is Dec 10, 2025, and Sep 29, 2025, respectively.
| Corona Remedies IPO | Jinkushal Industries IPO | |
|---|---|---|
| Anchor Bid Date | Dec 05, 2025 | Sep 24, 2025 |
| Issue Open | Dec 08, 2025 | Sep 25, 2025 |
| Issue Close | Dec 10, 2025 | Sep 29, 2025 |
| Basis Of Allotment (Tentative) | Dec 11, 2025 | Sep 30, 2025 |
| Initiation of Refunds (Tentative) | Dec 12, 2025 | Oct 01, 2025 |
| Credit of Share (Tentative) | Dec 12, 2025 | Oct 01, 2025 |
| Listing date (Tentative) | Dec 15, 2025 | Oct 03, 2025 |
| Anchor Lockin End date 1 | Jan 09, 2026 | Oct 29, 2025 |
| Anchor Lockin End date 2 | Mar 10, 2026 | Dec 28, 2025 |
Corona Remedies IPO P/E ratio is 43.47, as compared to Jinkushal Industries IPO P/E ratio of 18.8.
| Corona Remedies IPO | Jinkushal Industries IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Jinkushal Industries Ltd.'s revenue increased by 59% and profit after tax (PAT) rose by 3% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 72.5 | 100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 69 | 74.99 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 43.47 | 18.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹6495.20 Cr. | ₹464.42 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 27.50% | 28.30% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 41.32% | 18.39% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.10 | 0.58 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹24.43 | ₹6.43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 24.65% | 21.22% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Corona Remedies IPO Retail Individual Investors (RII) are offered 21,40,606 shares while in Jinkushal Industries IPO retail investors are offered 21,40,606 shares. Qualified Institutional Buyers (QIB) are offered 12,23,203 shares in Corona Remedies IPO and 19,19,143 shares in Jinkushal Industries IPO.
| Corona Remedies IPO | Jinkushal Industries IPO | |
|---|---|---|
| Anchor Investor Reservation | 18,34,804 shares | 28,78,500 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 12,23,203 shares | 19,19,143 shares |
| NII | 9,17,403 shares | 14,39,933 shares |
| RII | 21,40,606 shares | 33,61,972 shares |
| Employee | 58,035 shares | 0 shares |
| Others | ||
| Total | 61,74,051 shares | 95,99,548 shares |
Corona Remedies IPO subscribed 144.54x in total, whereas Jinkushal Industries IPO subscribed 65.09x.
| Corona Remedies IPO | Jinkushal Industries IPO | |
|---|---|---|
| QIB (times) | 293.80x | 35.70x |
| NII (times) | 220.18x | 146.39x |
| Big NII (times) | 246.67x | 141.05x |
| Small NII (times) | 167.20x | 157.05x |
| RII (times) | 30.39x | 47.04x |
| Employee (times) | 15.56x | |
| Other (times) | ||
| Total (times) | 144.54x | 65.09x |
